Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany

We compared the cost-utility analysis for edoxaban at both doses with that of dabigatran at both doses, rivaroxaban, and apixaban (non vitamin K antagonist oral anticoagulants, NOAC) in a German population. Data of clinical outcome events were taken from edoxaban's ENGAGE-AF, dabigatran's...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Biomed Res Int
Autori principali: Krejczy, Martin, Harenberg, Job, Wehling, Martin, Obermann, Konrad, Lip, Gregory Y. H.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Hindawi Publishing Corporation 2015
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4380099/
https://ncbi.nlm.nih.gov/pubmed/25853142
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2015/876923
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi